PROQR THERAPEUTICS EO-04 (F:0PQ) — Market Cap & Net Worth
Market Cap & Net Worth: PROQR THERAPEUTICS EO-04 (0PQ)
PROQR THERAPEUTICS EO-04 (F:0PQ) has a market capitalization of $159.61 Million (€136.53 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #17384 globally and #1629 in its home market, demonstrating a -13.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PROQR THERAPEUTICS EO-04's stock price €1.30 by its total outstanding shares 105345192 (105.35 Million).
PROQR THERAPEUTICS EO-04 Market Cap History: 2015 to 2026
PROQR THERAPEUTICS EO-04's market capitalization history from 2015 to 2026. Data shows change from $848.32 Million to $159.61 Million (-18.81% CAGR).
PROQR THERAPEUTICS EO-04 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PROQR THERAPEUTICS EO-04's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0PQ by Market Capitalization
Companies near PROQR THERAPEUTICS EO-04 in the global market cap rankings as of May 5, 2026.
Key companies related to PROQR THERAPEUTICS EO-04 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
PROQR THERAPEUTICS EO-04 Historical Marketcap From 2015 to 2026
Between 2015 and today, PROQR THERAPEUTICS EO-04's market cap moved from $848.32 Million to $ 159.61 Million, with a yearly change of -18.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €159.61 Million | -23.54% |
| 2025 | €208.76 Million | -34.86% |
| 2024 | €320.46 Million | +48.94% |
| 2023 | €215.16 Million | -43.90% |
| 2022 | €383.52 Million | -54.54% |
| 2021 | €843.64 Million | +94.60% |
| 2020 | €433.52 Million | -57.59% |
| 2019 | €1.02 Billion | -38.06% |
| 2018 | €1.65 Billion | +458.10% |
| 2017 | €295.71 Million | -46.51% |
| 2016 | €552.86 Million | -34.83% |
| 2015 | €848.32 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of PROQR THERAPEUTICS EO-04 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $159.61 Million USD |
| MoneyControl | $159.61 Million USD |
| MarketWatch | $159.61 Million USD |
| marketcap.company | $159.61 Million USD |
| Reuters | $159.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-sta… Read more